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Joann A. Boughman, PhD* Kyle M. Brown, PhD**

The Geneticists’ Approach to Bilski
THE PATENT PROCESS AND ITS ASSOCIATED CASE LAW HAVE become increasing familiar
to genetic research scientists and medical geneticists.1 For example, nearly
1% (19 of 3100) of researchers who applied to present research at the 2011
annual meeting of the American Society for Human Genetics reported a
possible or perceived financial conflict of interest based on their intellectual
property holdings.2 Guided by the interests of their members, professional
organizations of geneticists, like the American Society of Human Genetics
(ASHG) and others, have become responsive to and involved in the legal
processes involved with intellectual property protection.3 In Bilski v.
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1. See generally Alex Osterlind, Staking a Claim on the Building Blocks of Life: Human
Genetic Material within the United States Patent System, 75 MO. L. REV. 617 (2010) (discussing
the patentability of genetic material); D. Benjamin Borson, The Human Genome Projects:
Patenting Human Genes and Biotechnology. Is the Human Genome Patentable?, 35 IDEA 461,
461 (1995) (analyzing the legal issues surrounding patent protection of the products of studies of
the human genome). For additional information on genetic patents, see DAVID B. RESNIK,
OWNING THE GENOME: A MORAL ANALYSIS OF DNA PATENTING 50–55 (2004).
2. American Society of Human Genetics, 60th Annual Meeting Program, 361–63 (2010),
http://www.ashg.org/2010meeting/pdf/ASHG_program.pdf.
3. See, e.g., Brief for American Society of Human Genetics et al. as Amici Curiae
Supporting Plaintiffs’ Opposition to Defendants’ Motion To Dismiss and Supporting Plaintiffs’
Motion for Summary Judgment at 6, Ass’n for Molecular Pathology, et al. v. United States Patent
and Trademark Office, et al., 702 F.Supp.2d 181 (2009) (No. 09 Civ. 4515), 2009 WL 3269106
(S.D.N.Y.); Brief for The American College of Medical Genetics, et al. as Amici Curiae
Supporting Respondents at 1, Bilski v. Kappos, 130 S. Ct. 3218 (2010).
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Kappos,4 the Supreme Court ruled on the patentability of certain subject
matter for the first time in 30 years.5 The ruling has potential implications
for a variety of patentable “arts,” including medical and research genetics,
but the narrow scope of this ruling, in conjunction with other decisions, has
left significant uncertainty in the field of human genetics about what
constitutes patentable material.6
In order to continue producing innovative research and discoveries that
will contribute to the treatment of disease, genetics researchers need more
legal certainty about the patentability of genetic methods and materials.7 By
applying a current understanding of medical and research genetics to
questions of patentability, courts will be able to resolve ambiguities in
patent jurisprudence while stimulating innovation and access to the benefits
of genetically informed medicine.8
The genetics community has taken a balanced approach, embracing the
protection of intellectual property while fostering openness in research.9
However, recent court decisions and patent office precedents defy the
original intent of the patent process by allowing genetic patents that may be

4. 130 S. Ct. 3218 (2010).
5. See Diamond v. Diehr, 450 U.S. 175 (1981) (holding that process claims for curing rubber
were patentable despite including the use of a known equation); Parker v. Flook, 437 U.S. 584
(1978) (noting that method claims containing algorithms are not patentable); see also MJ Edwards
& Donald Steinberg, The Implications of Bilski: Patentable Subject Matter in the United States,
49 IDEA 411, 413 (2009) (noting that “the line between what is patentable and what is not is not
always clear. The Supreme Court addressed this line in a series of decisions that are now more
than twenty-five years old . . .”). Id.
6. See Chris Holman, The Impact of Bilski on Biotechnology, HOLMAN’S BIOTECH IP BLOG
(July 3, 2010, 11:22 AM), http://holmansbiotechipblog.blogspot.com (“[T]he Supreme Court
provided little if any guidance with respect to what it means for a patent to claim a fundamental
principle, and absolutely no guidance with respect to how to apply the test when the fundamental
principle is a biological natural phenomenon . . . .”).
7. See Jennifer Giordano-Coltart et al., No Legal Monopoly for Genes: Court Rules Genes
are Unpatentable Subject Matter, INTELL. PROP. & TECH. L.J. 8, 12 (2010) (discussing the
uncertainties presented by Supreme Court’s ruling and its chilling effect on genetic research and
innovation in the medical field).
8. See Holman, supra note 6 (suggesting that the Court should draw a line between
biological phenomena that occur absent human intervention and phenomena that occur as a result
of human intervention when determining what constitutes patentable subject matter in the genetic
context).
9. See Matthew Herper, Genome Scientists: Gene Patents are Bad, FORBES (June 26, 2002),
http://www forbes.com/2002/06/26/0626targets html (discussing the balance between gene patents
and accessibility of information). For additional information and an overview of the arguments
for and against gene patenting, see generally HUMAN GENOME PROJECT INFORMATION, Genetics
and Patenting, http://www.ornl.gov/sci/techresources/Human_Genome/elsi/patents.shtml. (last
modified July 7, 2010).
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detrimental to innovation and discovery.10 The courts should protect
intellectual property while recognizing the patent ineligibility of genetic
principles and naturally occurring gene sequences.
I. BASIC GENETIC METHODOLOGIES

As with many applications, the eligibility of specific discoveries and
inventions in the field of genetics hinge on a detailed understanding of the
technical details underlying the application.11 By understanding
fundamentals of genetics methodologies, the courts can better understand
whether an application represents a “new and useful process, machine,
manufacture or composition of matter.”12
Often described as a double helix, DNA can be conceptualized as a
twisted zipper that can be opened and closed.13 In this analogy, individual
chemicals make up the teeth of the DNA zipper.14 When closed, the zipper
is held together by forces similar to static electricity.15
Unlike zippers on your clothing, the teeth of DNA zippers come in
four different types.16 Symbolized by the letters A, C, T and G, the

10. See Joseph Stiglitz & John Sulston, The Case Against Gene Patents, WALL ST. J., Apr.
16, 2010, at A19 (stating that genetic patents inhibit access to basic information and may impede
scientific progress); see also RESNIK, supra note 1, at 202 (stating that “[p]atents on biological
materials, such as DNA, provide crucial incentives for this developing industry, but they also
threaten the progress of science, the practice of medicine, the development of agriculture, and the
preservation of cultural notions concerning the value of human life[]”); see Intellectual Property
Rights Must be Balanced with Research Needs to Realize Full Potential of Biomedical Research,
OFFICE OF NEWS AND PUB. INFO. (Nov. 17, 2005), http:// www8 nationalacademies.org/
onpinews/newsitem.aspx?RecordID=11487 (emphasizing the need for balance between protecting
research discoveries and granting access to these discoveries by awarding gene patents to some,
but not all genomic material).
11. See RESNIK, supra note 1, at 40 (noting that in DNA patenting courts require a detailed
and precise description of the DNA sequence to be patented (citing Regents of the Univ. of Cal. v.
Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997))).
12. 35 U.S.C. § 101 (2006); see generally Stiglitz & Sulston, supra note 10 (discussing the
complex nature of gene patents and how the Court’s future decisions should be based upon this
nature).
13. See ALVIN SILVERSTEIN ET AL., DNA 18 (2002) (describing DNA as a zipper); DANIEL
L. HARTL & ELIZABETH W. JONES, ESSENTIAL GENETICS: A GENOMICS PERSPECTIVE 7 (Lianne
Ames ed., 3d ed. 2002) (identifying the subunits of DNA as chemical constituents known as
bases).
14. HARTL & JONES, supra note 13, at 7.
15. The chemical components of DNA are partnered together by hydrogen bonds, where
hydrogen atoms on one strand are attracted to electronegative oxygen or nitrogen atoms on the
other. See HARTL & JONES, supra note 13, at 215.
16. See id. (describing the four bases in DNA as Adenine, Guanine, Thymine and Cytosine).
VOL. 6 NO. 1 2011
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presence of one type of “tooth” on one side of the “zipper” (e.g. an “A”),
dictates the identity of the tooth on the other side (in this case, a “T”).17 In
this way, the sequence of teeth on one side of the zipper — the DNA helix
—determines the sequence on the other side.18 Every time a human cell
divides, it “unzips” its DNA in order to create two exact replicas of its
genes, known as its genome.19
Research and diagnostic techniques take advantage of the zipper-like
qualities of DNA in order to read the sequence of A’s, T’s, C’s and G’s that
make up human genes and genomes.20 Methods that “read” patient DNA
sequences, like genome sequencing and microarrays, help detect specific
changes in the sequence of the DNA in a patient that may indicate an
increased risk for a specific disease or condition.21 These techniques do not
fundamentally alter or transform the DNA sequences that exist in nature;22
rather the DNA sequence is merely read.23
To read a patient’s genetic code, DNA is removed from cells through a
process known as DNA extraction.24 Methods for DNA extraction have
existed since the 19th century.25 Standard methods purify DNA from
organisms by breaking open cells and separating the DNA from other
17. Id. at 7–8.
18. See SILVERSTEIN ET AL., supra note 13.
19. See id. at 18 (explaining that when DNA replicates, the two sides of the helicase “split
down the middle at one end, like unzipping a zipper.”); See HARTL & JONES, supra note 13, at
210 (“The genetic complement of a cell or virus constitutes its genome.”).
20. See generally EDWIN H. MCCONKEY, HOW THE HUMAN GENOME WORKS 1–4 (Renee
Sekerak ed., 2004) (discussing DNA research and diagnostic techniques); see SILVERSTEIN ET
AL., supra note 13, at 38–39 (discussing the Human Genome Project and the development of
DNA research).
21. See A Brief Guide to Genomics, NAT’L HUMAN GENOME RESEARCH INST. (Aug. 24,
2010), http://www.genome.gov/18016863 (discussing the importance of genetic research in
understanding complex diseases and treatments); see also Genetic Testing, GENETICS & PUB.
POLICY CTR. (May 2006), http://www.dnapolicy.org/science.gt.php (“The results of genetic tests
can be used to diagnose genetic disease, predict risks of disease, and identify carriers of genetic
disease” and methods include DNA sequencing and microarrays).
22. See generally ROBERT A. BOHRER, A GUIDE TO BIOTECHNOLOGY LAW AND BUSINESS
27 (2007) (explaining DNA replication techniques); RESNIK, supra note 1, at 26 (noting that while
DNA replication is a natural process, it can be reproduced under laboratory conditions).
23. See BOHRER, supra note 22, at 27 (discussing how sequencing machines read).
24. See George Rice, DNA Extraction, MICROBIAL LIFE EDUCATIONAL RESOURCES,
http://serc.carleton.edu/microbelife/research_methods/genomics/dnaext html (explaining DNA
extraction).
25. Swiss biologist Friedrich Miescher carried out the first successful DNA extraction in
1868, though it was not until the 1940s that scientists discovered its genetic properties. See The
Search for DNA—The Birth of Molecular Biology, BIOTECH. INDUS. ORG. (1990),
http://www.accessexcellence.org/RC/AB/BC/Search_for_DNA.php.
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cellular components (e.g. proteins and lipids).26 Importantly, DNA
extraction procedures do not fundamentally transform the DNA or alter the
information encoded within it.27
Microarrays determine whether a patient’s DNA contains a specific
sequence by matching DNA molecules extracted from patient cells to those
of a known sequence.28 Microarray chips contain tens of thousands of
microscopic spots where DNA molecules of known sequence have been
attached to the surface of the slide.29 After a patient’s DNA is extracted, the
molecules are “unzipped,” separating the two sides of the DNA helix, and
tagged with a chemical that glows under laser light.30 The patient’s DNA is
then placed on a microarray chip.31 Under laboratory conditions, the singlestrand DNA from the patient’s DNA sample will attach to sequences on the
chip to which it matches.32 After allowing the patient’s DNA to find its
match on the chip, the chip is observed under a microscope.33 Spots that
glow indicate sequences that are contained within the patient’s DNA.34
DNA sequencing allows geneticists to read any portion of a patient’s
DNA without knowing the sequence in advance.35 Similar to microarrays,
the process relies on the complementary nature of DNA molecules.36
However, instead of matching entire DNA molecules to patient DNA,
26. See RESNIK, supra note 1, at 28 (outlining the process of isolating and purifying DNA).
27. See supra note 21 and accompanying text.
28. See HARTL & JONES, supra note 13, at 435 discussing microarrays as:
each containing a different immobilized DNA sequence suitable for hybridization with
DNA or RNA isolated from cells growing under different conditions, from cells not
exposed or cells exposed to a drug or toxic chemical, from different stages of
development, or from different types or stages of a disease such as cancer.
Id.
29. Id. (describing a microarray as a “flat surface about the size of a postage stamp on which
10,000 –100,000 distinct spots are present . . . .”).
30. Id. (describing the variously colored fluorescent labels).
31. Id. (“When a sufficient quantity of labeled DNA strands have accumulated, the
fluorescent samples are mixed and hybridized with the DNA chip.”).
32. Id.
33. See Patrick O. Brown & David Botstein, Exploring the New World of the Genome with
DNA Microarrays, 21 NATURE GENETICS SUPPLEMENT 33, 33 (Jan. 1999) (“After hybridization,
fluorescence measurements are made with a microscope . . . .”).
34. Id.
35. See T.A. BROWN, DNA SEQUENCING: THE BASICS 3–5 (1994) (outlining the steps of two
popular methods of reading a patent’s DNA, neither of which require knowing the sequence in
advance); see also NAT’L HUMAN GENOME RESEARCH INST., supra note 21 (“Sequencing simply
means determining the exact order of the bases in a strand of DNA.”).
36. See LUKE ALPHEY, DNA SEQUENCING: FROM EXPERIMENTAL METHODS TO
BIOINFORMATICS 5–6 (1997) (referring to the complimentary ability of DNA molecules).
VOL. 6 NO. 1 2011
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sequencing uses unzipped patient DNA as a template to build the
complementary strand of DNA (i.e. the other side of the DNA zipper) one
base pair at a time.37 Traditional methods, developed by Fredrick Sanger,
use procedures that simulate in test tubes the process of DNA replication
within living cells.38
Initially, a large number of copies of the region of DNA to be
sequenced are produced, and in order to read the sequence of these millions
of identical molecules, sequencing attempts to replicate these DNA
molecules again.39 However, these reactions periodically incorporate
specially labeled base pairs (e.g., A’s might be labeled green, T’s red, G’s
blue and C’s yellow) that terminate the growing DNA strand.40 When
completed, the reaction results in DNA molecules of every length in the
sequence.41 For example, if the DNA sequence to be read were GCTA, the
sequencing reaction would create molecules with the sequences G, GC,
GCT, and GCTA.42 By putting them through a molecular sieve, these
molecules can then be separated and arranged based upon size, and then
visualized to determine their color.43 So if the sequencing reaction creating

37. See HARTL & JONES, supra note 13 (“[E]ach strand of the double helix serves as a
template for the synthesis of a new strand . . . .”).
38. See F. Sanger & A.R. Coulson, A Rapid Method for Determining Sequences in DNA by
Primed Synthesis with DNA Polymerase, 94 J. MOL. BIOL. 441, 441 (1975) (describing “[a]
simple and rapid method for determining nucleotide sequences in single-stranded DNA by primed
synthesis with DNA polymerase . . . .”); see F. Sanger et al., DNA Sequencing with ChainTerminating Inhibitors, 74 PROCE. NAT’L. ACAD. SCI. U.S.A. 5463, 5463–67 (1977) (describing
DNA sequencing with chain-terminating inhibitors).
39. See HARTL & JONES, supra note 13, at 239 (“To obtain the sequence of a long stretch of
DNA, a set of overlapping fragments must be prepared, the sequence of each is determined, and
all sequences are then combined.”). See generally BROWN, supra note 35 (describing the process
of replicating the DNA molecules through the synthesis of complimentary polynucleotide chains
from existing single-stranded DNA molecules).
40. See BROWN, supra note 35, at 27 (“Strand synthesis is not allowed to continue to
completion as a chain terminating nucleotide . . . is included in the reaction mixture.”).
41. Id. at 4 (“The result is therefore a family of new chains, all of different lengths . . .”); see
also NAT’L HUMAN GENOME RESEARCH INST., supra note 21 (“Each of the fragments differs in
length by one base and is marked with a fluorescent tag that identifies the last base of the
fragment.”).
42. See BROWN, supra note 35, at 4–5 (Figure 1.4 illustrates the strand synthesis reaction
which results in a family of chains with overlapping sequences).
43. See HARTL & JONES, supra note 13, at 240 (“The fragments from all four sequencing
reactions are combined, the fragments are separated by size using electrophoresis in a gel or
capillary tube, and the dideoxy terminator is identified by its fluorescence.”).
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molecules that, from smallest to largest, were blue, yellow, red and green, a
researcher would know the sequence he was interested in read “GCTA.”44
However, knowing a patient’s DNA sequence is only the beginning.45
Even a decade after the publication of the first draft of the human genome,
researchers are only beginning to decipher the exceedingly complex
language encoded by human DNA.46
Understanding the language of the human genome is like translating a
foreign language. The human genome contains approximately 3 billion base
pairs, which encode approximately 20,000 genes.47 The function of many
of these genes is poorly understood, if not completely unknown.48 Even
when a gene’s function is known, it is seldom clear how mutations in that
DNA sequence will affect a patient’s health.49
With only a rudimentary understanding of the language of the human
genome, geneticists seek to connect the individual differences in patients’
DNA with their physical traits and diseases.50 But individual people differ
at thousands of locations in their genomes and have hundreds of different

44. See id. at 240–41 (illustrating the process through which a DNA sequence can be read
directly from the colored gel lanes).
45. See MCCONKEY, supra note 20, at 4 (“Completion of the human genome sequence is a
major milestone in human genetics, but it certainly does not mean that we know how all the genes
function.”); see also SANDY B. PIMROSE, PRINCIPLES OF GENOME ANALYSIS: A GUIDE TO
MAPPING AND SEQUENCING DNA FROM DIFFERENT ORGANISMS 7 (2d ed. 1998) (“Detailed
understanding of an organism will only be achieved when every gene has been identified and its
transcript and the timing of transcript synthesis known.”).
46. Geoffrey Carr, Biology 2.0: A Special Report on the Human Genome. THE ECONOMIST,
June 17th 2010 (“[Researchers] found that their methods for linking genetic variation to disease
were inadequate…however, these obstacles are falling away.”).
47. See NAT’L HUMAN GENOME RESEARCH INST., supra note 21.
Transcriptome,
http:
48. See
NAT’L HUMAN GENOME RESEARCH INST.,
//www.genome.gov/13014330 (last reviewed Nov. 26, 2010) (“The function of most genes is not
yet known.”).
49. See MCCONKEY, supra note 20, at 46 (describing how genetic and environmental factors
both can affect the probability that a clinical condition or disease will develop); see also J. Craig
Venter et al., The Sequence of the Human Genome, 291 SCIENCE 1304, 1348 (2001) (“The
sequence is only the first level of understanding of the genome. All genes and their control
elements must be identified; their functions, in concert as well as in isolation, defined; their
sequence variation worldwide described; and the relation between genome variation and specific
phenotypic characteristics determined.”).
Structural Variation,
50. See
NAT’L HUMAN GENOME RESEARCH INST.,
http://www.genome.gov/25521748 (last reviewed Aug. 24, 2010) (“However, we still do not
completely understand the ‘normal’ range of human variation present in populations to provide a
basis for understanding the variations that result in disease.”).
VOL. 6 NO. 1 2011

65

T G’ A  B

physical traits.51 In order to determine the genetic changes that result in a
given disease or physical trait, geneticists use statistical methods and
algorithms to compare the DNA of hundreds of people with a disease or
trait and determine which changes commonly contribute to the disease.52
By using well-established statistical methods and large numbers of
patients, geneticists are beginning to identify changes in individuals that
might lead to a greater susceptibility to a given disease or physical trait.53
And as technologies advance and the cost of determining an individual’s
DNA sequence continues to fall, studies that associate disease with
particular changes in patients’ DNA have become common.54 Many studies
have focused on rare diseases that are caused by a small number of genetic
changes.55 Genome Wide Association Studies56 have also sought out the
genetic changes that influence a person’s risk for complex, common
diseases like heart disease, obesity, and autism, while trying to understand
how a patient’s environment may exacerbate or minimize the risk of these
diseases.57

51. Lynn B. Jorde & Stephen P. Wooding, Genetic Variation, Classification, and ‘Race,’ 36
NATURE GENETICS S28, S28 (2004) (“[E]ach pair of humans differs, on average, by two to three
million base pairs.”); See NAT’L HUMAN GENOME RESEARCH INST., Genetic Variation Program,
(“Most of any one person’s DNA, about 99.5 percent, is exactly the same as any unrelated
person’s DNA.”).
52. See generally Richard Mayeux, Mapping the New Frontier: Complex Genetic Disorders,
115 J. CLIN. INVEST. 6, 1405–8 (2005) (discussing specific methods that geneticists use to identify
“disease genes”).
53. Id. at 1404 (“The remarkable achievements in human genetics over the years have been
due to technological advances in gene mapping and in statistical methods that relate genetic
variants to disease.”).
A partial list of DNA-based tests can be found at
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.shtml.
HUMAN
GENOME PROJECT INFO., supra note 9.
54. See HUMAN GENOME PROJECT INFO., Facts About Genome Sequencing,
http://www.ornl.gov/sci/techresources/Human_Genome/faq/seqfacts.shtml (last modified Sept. 19,
2008) (describing the increase of sequencing output from 200 million base pairs in 1998 to 1.5
billion bases for the month of January 2003).
55. Sarah B. Ng et al., Targeted Capture and Massively Parallel Sequencing of 12 Human
Exomes, 461 NATURE 272, 272 (2009).
56. See NAT’L HUMAN GENOME RESEARCH INST., Genome Wide Association Studies,
http://www.genome.gov/20019523 (last reviewed Aug. 17, 2010) (“A genome-wide association
study is an approach that involves rapidly scanning markers across the complete sets of DNA, or
genomes, of many people to find genetic variations associated with a particular disease.”).
57. See Mayeux, supra note 52, at 1404, 1407 (stating that “the challenge now is to dissect
common complex genetic disorders such as obesity, diabetes, schizophrenia, and cancer” and
describing the “relatively new field of genetic epidemiology” as studying the joint effects of
environmental and genetic risk factors related to disease).
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Once DNA changes associated with specific diseases are known, the
hope is to sequence new patients’ DNA and predict the types of diseases to
which a given patient may be susceptible.58 Traditional genetic tests, such
as Myriad’s BRCA1/2 test for breast/cervical cancer,59 sequence individual
genes in order to make predictions about a small number of diseases.60
Other companies attempt to leverage the advances of Genome Wide
Association studies to predict consumers’ risks of common diseases.61
However, the direct-to-consumer genetic tests from companies like
23andMe,62 Navigenics,63 and Pathway Genomics64 have come under
severe scrutiny recently for giving consumers conflicting predictions about
their disease risk.65
II. INTELLECTUAL PROPERTY AND THE GENETICS COMMUNITY

As technologies and methodologies have progressed, the genetics
community has embraced a balanced approach to intellectual property,
protecting invention while promoting the exchange of scientific data and
discovery.66 For example, the Bayh-Dole Act67 has helped to incentivize
the application of genetic discoveries to the marketplace by vesting the
rights to the intellectual property resulting from federally funded research in

58. See HUMAN GENOME PROJECT INFO., supra note 9 (discussing the hope that after
technological improvements health professionals will be able to give patients individual
information regarding their risks of developing specific diseases).
59. See RESNIK, supra, note 1, at 159–60 (providing background on Myriad Genetics).
60. Id. (describing the BRCA1/2 test).
61. See, e.g., DeCODE Your Health, DECODEME, https://www.decodeme.com/completegenetic-scan (offering for sale a complete genetic scan to determine one’s risk to “many of the
most common diseases” including heart attack, diabetes, and baldness).
62. See Andrew Pollack, California Licenses 2 Companies to Offer Gene Services, N.Y.
TIMES, Aug. 20, 2008, at C3 (describing the services being offered by 23andMe and Navigenics).
63. Id.
64. See Andrew Pollack, Outlook Uncertain, N.Y. TIMES, Mar. 20, 2010, at B1 (discussing
the role of Pathway Genetics in the direct-to-consumer genetic testing market).
65. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-10-847T, DIRECT-TO-CONSUMER GENETIC
TESTS: MISLEADING TEST RESULTS ARE FURTHER COMPLICATED BY DECEPTIVE MARKETING
AND OTHER QUESTIONABLE PRACTICES, HEARING BEFORE THE SUBCOMM. ON OVERSIGHT AND
INVESTIGATIONS AND H. COMM. ON ENERGY AND COMMERCE, 4–5 (2010), available at
http://www.gao.gov/new.items/d10847t.pdf (discussing a special investigation of direct-toconsumer genetic testing companies that called into question the validity of their services).
66. See NAT’L HUMAN GENOME RESEARCH INST., Intellectual Property and Genomics,
http://www.genome.gov/19016590 (last updated Nov. 16, 2010) (discussing competing interests in
the genetics community regarding the strength of intellectual property protection).
67. 35 U.S.C. §§ 200–12 (2006).
VOL. 6 NO. 1 2011
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the academic institutions that receive the federal grant.68 Many new and
emerging biotechnology companies are based on proprietary intellectual
property in genetics,69 and use intellectual property as the basis for
garnering venture funds for their growth and development.70
But even as eligibility for patents can incentivize invention and
innovation,71 excessively designating new discoveries as proprietary may
also have a chilling effect on research.72 As the human genome project
accelerated, the genetics community recognized the importance of
balancing patent rights with the open exchange of scientific data and
information.73 In 1996, members of the genetics community, including
68. See RESNIK, supra note 1, at 70 (discussing the history of the Bayh-Dole Act); see also 35
U.S.C. §§ 200–12 (2006).
69. See MICHAEL H. BRODOWSKI ET. AL., BIOTECHNOLOGY AND THE LAW 25 (Eileen Smith
Ewing and Hugh B. Wellons eds., 2007) (explaining that life science companies depend on patents
as the foundation of the company); see Bryn Williams-Jones, History of a Gene Patent: Tracing
the Application and Development of Commercial BRCA Testing, 10 HEALTH L.J. 123, 126 (2002)
(following the Supreme Court’s decision in Diamond v. Chakarbarty, biotechnology start-up
companies increased in number between 1992 and 2002 and were largely based on a genetic
patents).
70. See e.g., RESNIK, supra note 1, at 67 (explaining that biotech companies, such as Celera
Genomics, which spent $200 million on research and development between 1997–2001 without
making a profit, depended heavily on patents for their development).
71. See id. at 70–71 (explaining DNA patents have provided industry with an incentive to
invest billions annually in basic and applied research, and the importance of the private sector’s
contribution); Clarisa Long, Patents and Cumulative Innovation, 2 WASH. U. J.L. & POL’Y 229,
230–31 (2000) (explaining that proprietary intellectual property drive innovation because without
these rights, inventors would lack incentives to create as they would not be able to recoup the full
value of their invention); Arti K. Rai, Intellectual Property Rights in Biotechnology: Addressing
New Technology, 34 WAKE FOREST L. REV. 827, 828–29 (1999) (“Patents promote invention by
giving individuals a monetary incentive to devote resources to such invention. Without a patent
right, the inventor might not be able to recoup her investment in a socially valuable, but cheaply
copied, product.”). But see Timothy Caulfield, Human Gene Patents: Proof of Problems?, 84
CHI.-KENT L. REV. 133, 135–36 (2009) (stating there is little empirical evidence that patents are
required for the innovation process).
72. See RESNIK, supra note 1, at 141 (discussing the research community’s aversion to
sharing data in order to protect intellectual property claims, with empirical evidence, and growing
trend in the life sciences is to withhold or delay publication of data to allow time for patent
protection); see also Bryan Nese, Bilski on Biotech: The Potential for Limiting Negative Impact
of Gene Patents, 46 CAL. W. L. REV. 137, 155–56 (2009) (discussing how gene patents can cause
excessive delays in research when scientists must obtain a license to conduct research on patented
genes or over hesitation to share data in an effort to protect patent eligibility).
73. See RESNIK, supra note 1, at 4–5. In the 1990’s as the Human Genome Project was
underway, competition between the public and private efforts developed over the issue of public
access to data. See id. at 4. The company Celera Genomics planned to charge institutions a fee to
access data in advance and to patent portions of the human genome DNA sequences. See id.
However, by 2000, Celera and the National Human Genome Research Institute arrived at a
consensus on data sharing and both published versions of the human genome in scientific journals.
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members of the human genome project, agreed that human genome
sequences “should be freely available and in the public domain in order to
encourage research and development and to maximize its benefit to
society.”74 These principles formed the basis of the National Human
Genome Research Institute’s Policy for Release and Database Deposition of
Sequence Data.75
Embracing not only patents but also public access, geneticists have led
the scientific community in the development of publicly accessible
databases.76 The National Institutes of Health77 (NIH) supports a variety of
publicly accessible databases for gene sequences and information from
humans and other organisms.78 For example, dbGaP (database of

See id. at 4–5. But see Melissa L. Sturges, Who Should Hold Property Rights to the Human
Genome? An Application of the Common Heritage of Humankind, 13 AM. U. INT'L L. REV. 219,
237–38 (1997 –1998). Private companies had several reasons why they felt patent protection was
necessary to forward research on genome sequences, including the monetary incentive provided
by patents as a motivation for researchers to complete the human genome sequence faster. Id. at
238.
74. See HUMAN GENOME PROJECT INFO., Summary of Principles Agreed at the First
International Strategy Meeting on Human Genome Sequencing, http://www.ornl.gov/sci/
techresources/Human_Genome/research/bermuda.shtml (last modified Oct. 29, 2003).
75. See NAT’L HUMAN GENOME RESEARCH INST., NHGRI Policy for Release and Database
Deposition of Sequence Data, http://www.genome.gov/page.cfm?pageID=10000910
(last
reviewed Aug. 2006). The National Human Genome Research Institute’s (NHGRI) policy for
release and deposition of DNA sequence data intended to make genome sequence information
publically accessible for free within 24 hours of obtaining data 2 kb or larger. Id.
76. See, e.g., Bruno J. Stasser, GenBank—Natural History in the 21st Century?, 322 SCIENCE
537, 537 (2008) (describing the meeting of scientists in March 1979 to develop a national DNA
sequence database); The First Public Nucleotide Sequence Database Turns 25, EUROPEAN
MOLECULAR BIOLOGY LAB. (May 22, 2007), http://www.ebi.ac.uk/embl/News/news html
(explaining the nucleotide sequence database, EMBL-Bank, was the first publically accessible
database of DNA and RNA sequences); National Institute of Health News, GenBank Celebrates
25 Years of Service with Two-Day Conference; Leading Scientists Will Discuss the DNA Database
at April 7-8 Meeting, NIH NEWS (April 3, 2008), http://www nih.gov/news/health/apr2008/nlm03 htm (discussing the origination of GenBank, a nucleic acid sequence database, that was created
by scientists in 1982 as a way for research groups to compare protein and DNA sequencing data).
77. The National Institutes of Health (NIH) is federal agency composed of over 27 institutes
and under the U.S. Department of Health and Human Services. See About NIH, The Nation’s
Medical Research Agency, NAT’L INST. OF HEALTH, http://www nih.gov/about/NIHoverview html
(last updated June 19, 2007). The NIH is a leading institute in medical and scientific research to
improve the health of the nation. See id.
78. See NLM Databases & Electronic Resources, U.S. NAT’L LIBRARY OF MED.,
http://www.nlm nih.gov/databases/ (last updated Sept. 17, 2010). The National Library of
Medicine website at the National Institutes of Health contains an alphabetical listing of all of
NIH’s publically accessible databases, including all the genetic databases.
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Genotypes and Phenotypes)79 is a publicly accessible, web-based database
that connects human gene sequences known as genotypes, with their
associated diseases and conditions, known as phenotypes.80 Data within
dbGaP are clearly identified as “pre-competitive”81 and the NIH expects
funded researchers to provide a data sharing plan.82 However, there are
certain protections of proprietary data, but these exceptions must be
discussed with the NIH.83
III. GENETIC PATENTS IN THE COURTS

The genetics community has sought to foster innovation by balancing
intellectual property claims with the promotion of public access to research
data.84 However, the U.S. Patent Office and the courts have, at times,
extended patent protections to claims that seem to upset this fragile
balance.85 While there is little doubt about the patentability of new, useful

79. NAT’L CENTER FOR BIOTECH. INFO., dbGap Genotypes and Phenotypes,
http://www ncbi nlm nih.gov/gap (last visited Sept. 24, 2010).
80. See Matthew D. Mailman et al., The NCBI dbGaP Database of Genotypes and
Phenotypes, 39 NATURE GENETICS 1181, 1181 (2007) (explaining dbGaP allows for public access
to large-scale data sets in order to analyze how genetic traits are associated with phenotypic
disease traits).
81. See NAT’L CENTER FOR BIOTECH. INFO., supra note 79 (“The data in dbGaP will be precompetitive, and will not be protected by intellectual property patents.”).
82. U.S. DEP’T OF HEALTH & HUMAN SERVS., NIH Data Sharing Policy and Implementation
Guidance:
Goals
of
Data
Sharing,
http://www.grants.nih.gov/grants/policy/data_
sharing/data_sharing_guidance htm (last updated Mar. 5, 2003) (“To facilitate data sharing,
investigators submitting a research application requesting $500,000 or more of direct costs in any
single year to NIH on or after October 1, 2003 are expected to include a plan for sharing final
research data for research purposes, or state why data sharing is not possible.”).
83. See id. (“NIH recognizes the need to protect patentable and other proprietary data. Any
restrictions on data sharing due to co-funding arrangements should be discussed in the datasharing plan section of an application and will be considered by program staff.”).
84. See Rebecca S. Eisenberg & Richard R. Nelson, Public vs. Proprietary Science: A
Fruitful Tension?, 131 DAEDALUS 89, 99 (2002) (explaining the importance of both private and
public research as private competition encourages more frequent discoveries while free access to
data allows for free access to genetic information and improves the completeness of proprietary
databases). See generally Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial
Incentives with Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65 (2002). But see, Matthew J.
Higgins & Stuart J. H. Graham, Balancing Innovation and Access: Patent Challenges Tip the
Scales, 326 SCIENCE 370, 370 (2009) (proposing that the focus on public access to generic
pharmaceuticals has tipped the balance “away from the incentives needed to support innovation”).
85. See Andrews, supra note 84, at 89–91 (discussing examples of patents that disrupt the
balance between protecting proprietary rights and the delivery of health care services, such as
private ownership of the rights to the genetic tests for the Alzheimer’s disease and breast cancer
genes and each owner’s refusal to let other labs conduct these tests independently).
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and novel machines that carry out genetic methodologies, recent case law
leaves many questions about the eligibility of genetic processes and the
genetic material which they utilize.86
A. Process Claims
The Supreme Court has consistently ruled that algorithms, mathematical
formulas and other statistical methodologies, are rarely, if ever eligible for
patents.87 As discussed above, these methodologies are at the heart of
genetic diagnostics, associating specific genetic changes with increased risk
of disease.88 In Gottshalk v. Benson89 and Parker v. Flook,90 the Supreme
Court ruled that the discovery of new and useful mathematical formulas or
the application of such formulas is not eligible for patents.91
In Bilski v. Kappos,92 the Supreme Court maintains this precedent by
ruling that mathematical algorithm for hedging financial risk is not eligible

86. See e.g., Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F.
Supp. 2d 181, 230–31 (S.D.N.Y. 2010) (as amended Apr. 5, 2010) (finding Myriad’s gene patents
related to the breast cancer genes BRCA1 and 2 invalid because the purified DNA segments
claimed were not markedly different from that found in nature and were the result of natural
phenomena); Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 137–38 (2006)
(Breyer, J., dissenting) (arguing a patent on a process of correlating results to detect vitamin B and
folic acid deficiencies is invalid because the process is no more than an “unpatentable ‘natural
phenomenon’”); see also Michael L. Shuster & Juleen Konkel, Of Babies and Bathwater—The
Impact of In re Bilski on Life Science Patents, 1 HASTINGS SCI. & TECH L.J.153, 154 (2009)
(reviewing recent cases that help define the scope of patentable subject matter in the life sciences).
87. See, e.g., Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010) (majority opinion) (finding a
patent on risk hedging ineligible because the concept of hedging is essentially a mathematical
formula, an unpatentable abstract idea); Diamond v. Diehr, 450 U.S. 175, 185 (1981) (explaining
“laws of nature, natural phenomena, and abstract ideas” are subject matter excluded from patent
protection); Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (as laws of nature, physical
phenomena, and abstract ideas have been held not patentable, neither Einstein’s “E=mc2” nor
Newton’s law of gravity could be found patentable subject matter); see also cases cited infra notes
89–90 and accompanying text.
88. See Mailman et al., supra note 80, at 1185 (describing various statistical methods used to
ensure high quality genotypic data).
89. 409 U.S. 63 (1972).
90. 437 U.S. 584 (1978).
91. Parker, 437 U.S. at 594 (holding algorithm used for calculating chemical processes
involved in catalytic conversion was not patent eligible because the algorithm only provided an
improved method for calculating well known chemical processes); Gottschalk, 409 U.S. at 68
(holding mathematical formula to convert binary code into binary numbers for use in computers
was an abstract idea, not a patent eligible process).
92. 130 S. Ct. 3218 (2010).
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for patent.93 However, in concurring with the circuit court’s decision,94 the
Supreme Court held that a process need not be “tied to a particular machine
or apparatus”95 or transform “a particular article into a different state of
thing” in order to be patent eligible.96 Rejecting this “machine or
transformation test,”97 the Court ruled that the method in question was
unpatentably abstract and did not pass the non-obviousness criteria.98
While the decision in Bilski seemingly upholds the precedent that
mathematical formulas and algorithms are not patentable,99 the Supreme
Court’s opinion expands the definition of a patent eligible process.100 The
Court notes that “[p]atents for inventions that did not satisfy the machineor-transformation test were rarely granted in earlier eras. . . but times
change.”101 Struggling to apply patent law to “unforeseen innovations,”102
the Court notes that it “is unaware of any ‘ordinary, contemporary or
common meaning,’ of the definitional terms ‘process art or methods’ that
would require these to be tied to a machine or transform an article.”103 But
as the Court seeks to expand the definition of a patentable process to meet
the needs of the information age, it refuses to give guidance on the limits of
patentable process.104 The Court states:
[T]he patent law faces a great challenge in striking the balance
between protecting inventors and not granting monopolies over
93. Id. at 3231 (finding that allowing a patent on hedging financial risk would be the same as
patenting an abstract idea).
94. In re Bilski, 545 F.3d 943 (Fed. Cir. 2008).
95. Bilski, 130 S. Ct. at 3325.
96. Id.
97. See id. at 3227.
98. See id. at 3230.
99. See id. at 3231 (“The concept of hedging, described in claim 1 and reduced to a
mathematical formula in claim 4, is an unpatentable abstract idea, just like the algorithms at issue
in Benson and Flook.”).
100. See id. at 3224 (finding that the machine-or-transformation test, which allows patents on
processes that are linked to a machine or that transform something into a different state, is not the
only test for determining patent eligibility); see also William J. Simmons, Bilski v. Kappos: The
U.S. Supreme Court Broadens Patent Subject-Matter Eligibility, 28 NATURE BIOTECHNOLOGY
801, 805 (2010) (The Bilksi Court expanded the range of patentable subject matter by “holding
that the machine-or-transformation test is not the sole test for patent eligibility in the US and the
types of patent-eligible subject matter are vast.”).
101. Bilski, 130 S. Ct. at 3227.
102. Id.
103. Id. (citing Diamond v. Diehr, 450 U.S. 175, 182 (1981)).
104. Simmons, supra note 100, at 805 (2010) (observing that the Court declined to articulate “a
generic test that would distinguish a patentable method from an abstract idea”).

72

JOURNAL OF BUSINESS & TECHNOLOGY LAW

B  B

procedures that others would discover by independent, creative
application of general principles. Nothing in this opinion should
be read to take a position on where that balance ought to be
struck.105
By refusing to rule on the limits of process patentability, the Court
leaves genetic patents in an uncertain state.106 Genetic methodologies,
including algorithms that associate genetic changes with disease, may be
poised to revolutionize diagnostics and personalize medicine.107 However,
excessive granting of patents may have a chilling effect on research,
limiting the scientific progress that the patents are designed to
encourage.108 Further, the current uncertainty resulting from the Bilski
decision may be more problematic because it may lead to the inconsistent
handling of patents by the courts or the United States Patent and Trademark
Office (USPTO), and subsequently, years of lawsuits and reluctance from
investors.109
By expanding the definition of patentable processes, the Bilski
decision is immediately relevant to the eligibility of patent claims at issue in
Prometheus Laboratories, Inc. v. Mayo Collaborative Services.110 The
patent at issue related to a diagnostic process where a drug was
administered to a patient and then the patient was tested for the presence of
a particular chemical, known as a metabolite, that would not have been
105. Bilski, 130 S. Ct at 3228.
106. See Simmons, supra note 100, at 805 (noting the biotech industry’s lack of guidance as to
what is patentable subject matter under the Court’s Bilski framework for “future innovations such
as those emerging in the life sciences”).
107. See Aleksander S. Popel & Peter J. Hunter, Systems Biology and Physiome Projects, 1
WILEY INTERDISCIPLINARY REVIEWS: SYS. BIOLOGY AND MED. 153, 153 (2009) (recognizing
that systems approaches in fields such as genomics and proteomics are poised to revolutionize
medicine); see also NAT’L HUMAN GENOME RESEARCH INST., Fact Sheet: Genome-Wide
Association Studies, http://www.genome.gov/20019523 (last reviewed Aug. 17, 2010) (stating that
genome-wide association studies are laying the foundation for a new era of personalized
medicine).
108. See Stiglitz & Sulston, supra note 10, at A19 (stating that the granting of gene patents
“not only prevent the use of knowledge in ways that would most benefit society, they may even
impede scientific progress”).
109. See Jonathan Masur, Patent Inflation, 2–3, 5, 33–34 (Chicago Law Sch. Pub. Law &
Legal Theory Working Paper Grp., Paper No. 316, 2010), available at http://
papers.ssrn.com/sol3/papers.cfm?abstract_id=1623929 (anticipating that inconsistent application
of patents and the uncertainty of patent validity that stems from such application due to decisions
such as Bilski could lead to the granting of invalid patents which can “hamper a firm’s ability to
raise capital or write contracts with potential customers”).
110. 581 F.3d 1336 (Fed. Cir. 2009); see also infra notes 111–22 and accompanying text.
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present in the patient in the drug’s absence.111 The patent correlated the
level of metabolite in the patient with the need to change the drug’s dose in
order to “minimize [drug] toxicity and maximize efficacy of treatment.”112
A central issue in the lawsuit concerned whether the patent claims are
“transformative.”113 While the district court invalidated the patent, arguing
that the claim represented merely data gathering and mental steps,114 the
circuit court reversed, arguing that the “claims are to transformative
methods of treatment, not correlations.”115
The patent claims in Prometheus are not fundamentally different from
other diagnostic methods.116 The circuit court argued that that the patents
are “claims to methods of treatment, which are always transformative”
when treatments involve drugs administered for the treatment of disease.117
However, medical practice and diagnosis is inherently empirical, requiring
the administration of treatments, the evaluation of their efficacy, and the
adjustment of treatment.118 Many drugs have toxic or undesired side effects
and a patient’s correct dose can often only be determined by administering
the drug and testing how the patient responds.119
If the circuit court’s ruling in Prometheus is allowed to stand under
Bilski’s expansive and uncertain definition of a patentable process, medical
diagnostics, including those that use standard genetic methodologies to
111. Prometheus, 581 F.3d at 1339.
112. Id.
113. See id. at 1347.
114. Id. at 1341.
115. Id. at 1349.
116. Id. at 1339. See Brian P. Murphy & Daniel P. Murphy, Bilski’s “Machine-orTransformation” Test: Uncertain Prognosis for Diagnostic Methods and Personalized Medicine
Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 755, 773 (2009) (noting that the
Prometheus claims for “determining the proper dosage of thiopurine drugs” including the drugs 6mercaptopurine and azathiopurine which “have been used for years to treat autoimmune
diseases”).
117. Prometheus, 581 F.3d at 1346.
118. See Diederick E. Grobbee, Epidemiology in the Right Direction: The Importance of
Descriptive Research, 19 EUR. J. OF EPIDEMIOLOGY 741, 741–42 (2004) (explaining that
empirical documentation of a medical diagnosis requires a study and sampling of cases).
119. See Jürgen Brockmöller & Mladen V. Tzvetkov, Pharmacogenetics: Data, Concepts and
Tools to Improve Drug Discovery and Drug Treatment, 64 EUR. J. CLINICAL PHARMACOLOGY
133, 139 (2008) (advocating for individualized drug therapy because “the choice of the drug and
the choice of drug dosing regimens” ought to be “selected based on the patient’s individual
requirements”); see also William E. Evans & Mary V. Relling, Moving Towards Individualized
Medicine with Pharmacogenomics, 429 NATURE 464, 464 (2004) (observing that differences in
DNA sequences means that individuals respond differently to drugs and therefore patients should
have their proper dosage tested).
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correlate DNA sequences with specific diseases, may be patentable.120
Such an expansive definition would likely limit research and access to
treatment as a select few laid claim to specific genetic associations and their
clinical applications.121
B. Claims on Gene Sequences
Genetic processes often require the use of specific genetic materials, such as
gene sequences or genetically modified organisms.122 With the accelerated
progress of the life sciences,123 the courts, Congress, and the USPTO have
been increasingly willing to grant patents on claims regarding genes and
living organisms.124 However, because versions of patented sequences exist
in the DNA of nearly every human being,125 the granting of patents for
claims of specific gene sequences themselves allows for the patenting of
naturally occurring phenomena while preventing individuals from knowing
their own DNA sequences.126

120. See Jeffrey R. Kuester & Steve D. Perkins, In the Aftermath of Bilski v. Kappos, in
PATENT LITIGATION 2010, at 20 (PLI Intell. Prop., Course Handbook Ser. No. 24179, 2010)
(“Although the law remains unsettled, the biotechnology field perhaps enjoys a higher level of
sympathy.”); see also Wayne A. Keown, Short Circuit: How Will Bilski v. Kappos Inform the
Federal Circuit on Medical Diagnostic Patents?, PRETI FLAHERTY (June 28, 2010),
http://www.preti.com/How-will-Bilski-affect-medical-diagnostic-patents (concluding that if
Prometheus is allowed to stand under Bilski, the considerations will support medical diagnostic
procedures as patentable subject matter).
121. Simmons, supra note 100, at 803 (“Regarding limiting interference with the development
of nascent technologies, such as biotechnology and biopharmaceuticals, the court indicated that
some types of inventions ‘raise special problems in terms of vagueness and suspect validity’ and
could ‘put a chill on creative endeavor and dynamic change.’”).
122. BOHRER, supra note 22, at 42 (Carolina Academic Press 2007) (discussing the genetic
process of a cell and genetically modified organisms).
123. See Popel & Hunter, supra note 107, at 153 (“[T]he revolution in biology and progress in
genomics and proteomics is now beginning to affect medicine.”).
124. See Murphy & Murphy, supra note 116, at 759–60 (commenting on the Court’s caution
“against reading limitations into the patent laws not expressed by the legislature” and that even
“where an inventor discover[s] a previously unknown natural law or phenomenon” as in some
diagnostic method claims, there may still be a patentable invention if the application of the natural
law produces a new and useful end).
125. See generally Richard Redon et al., Global Variation in Copy Number in the Human
Genome, 444 NATURE 444, 444–54 (2006) (noting that gene sequences across individual human
beings are nearly identical, which means that any patented DNA sequence will exist in most
human beings).
126. See Aykut Çoban, Genomic Information and the Public-Private Imbalance, 2008
CAPITAL & CLASS 71, 81–82 (stating that the “co-modification and ownership of the components
of living entities[,]” such as genes and DNA sequences, “through patents raises ethical and legal
issues”).
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Recent court cases have expanded traditional interpretations of
patentable subject matter in order to expand patent protections into the field
of genetic engineering.127 In Diamond v. Chakrabarty,128 the Supreme
Court ushered in a new era by ruling that genetically modified organisms
could be patented.129 Since Chakrabarty, patent law has also begun to
evolve and now specifically enumerates some of the biotechnological
processes that are patent eligible, including genetically modified
organisms.130
While Congress intended patents to extend to “include anything under
the sun that is made by man,”131 naturally-occurring DNA sequences
themselves, as they exist in human beings, fall outside patent eligible claims
under 35 U.S.C. § 101.132 Despite these prohibitions, patent claims have
been granted on “isolated” DNA sequences on the basis that isolation of
DNA from the human body “renders it patentable by transforming it into
something distinctly different in character.”133 But geneticists are skeptical
of this false distinction because they recognize that isolating DNA from
human cells does not fundamentally alter its information content or
chemical structure.134 The fact that isolated DNA can be reinserted into
patients and retain its original function is the basis for gene therapy
research, disease treatments that may soon allow doctors to “fix” parts of a

127. See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 125, 125 (2006)
(dismissing writ of certiorari and maintaining the Federal Circuit court decision ruling that
Metabolite could patent its discovery of the correlation of amino acid levels with B vitamin levels,
expanding patent protection to genetic engineering).
128. 447 U.S. 303 (1980).
129. Id. at 318 (“[U]ntil Congress takes such action, this Court must construe the language of §
101 as it is. The language of that section fairly embraces respondent’s invention.”).
130. 35 U.S.C. § 103(b) (1999).
131. See S. REP. NO. 82-1979 (1952); see also SECRETARY’S ADVISORY COMM. ON GENETICS,
HEALTH, AND SOCIETY, U.S. DEP’T OF HEALTH & HUM. SERVS., GENE PATENTS AND LICENSING
PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 57 (2010) [hereinafter
SACGHS
Report],
available
at
http://oba.od nih.gov/oba/sacghs/reports/SACGHS_
patents_report_2010.pdf.
132. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181,
233–37 (S.D.N.Y. 2010) (finding that the methods of analyzing isolated DNA gene sequences to
identify mutations relating to breast cancer predisposition were not patentable subject matter
under the machine-or-transformation test).
133. Id. at 185.
134. See id. at 199 (“In the context of a gene or a portion of the genome, sequencing is
designed to illuminate the information that nature has dictated in that person’s genome, and the
sequencing process, by design, does not alter the information content of the native DNA
sequence”).

76

JOURNAL OF BUSINESS & TECHNOLOGY LAW

B  B

patients’ DNA that will cause disease.135 Despite reservations from many
geneticists, approximately 20% of all human gene sequences have been
patented.136
In Ass’n for Molecular Pathology v. United States Patent Office,
(hereinafter Myriad),137 the United States District Court of Southern New
York invalidated patents related to the gene sequence of the BRCA1 and
BRCA2,138 certain versions of which make the women who posses them
more likely to contract breast and cervical cancer.139 In its ruling, the
district court found that “isolated DNA containing sequences found in
nature are unsustainable as a matter of law and are deemed unpatentable
subject matter under 35 U.S.C. § 101.”140 While the court’s decision may
have implications for gene patenting as a whole, the court confined its
ruling to the patents at issue and patents representing other genes remain
valid.141
By invalidating the patent claims, the court combined a detailed
understanding of genetic science with relevant case law.142 The Supreme
Court has consistently held that “products of nature do not constitute
patentable subject matter absent a change that results in the creation of a
fundamentally new product”143 and that “‘purification’ of a natural
compound, without more, is insufficient to render the product of nature
patentable.”144 Given the non-transformative and purifying nature of DNA

135. See Richard C. Mulligan, The Basic Science of Gene Therapy, 260 SCIENCE 926, 926
(1993) (explaining the methods of gene therapy involve introducing DNA sequences into cells to
treat human disease).
136. See Kyle Jensen and Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 SCIENCE 239, 239 (2005) (finding that “nearly 20% of human genes are explicitly
claims as U.S. IP” and 4,382 of the 23,688 genes in the National Center for Biotechnology
Information database are patented).
137. 702 F. Supp. 2d 181 (S.D.N.Y. 2010) [hereinafter Myriad].
138. Id. at 185.
139. Id. at 203 (“Mutations in the BRCA1/2 genes correlate with an increased risk of breast and
ovarian cancer.”); see also Jeffery P. Struewing et al., The Risk of Cancer Associated with Specific
Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews, 336 NEW ENG. J. MED. 1401, 1401
(1997) (“Current estimates of the risk of breast cancer in a woman who carries a BRCA1 or
BRCA2 mutation . . . range from 76 to 87 percent.”).
140. Myriad, 702 F.Supp.2d at 185.
141. See id.
142. See infra notes 143–46 and accompanying text.
143. Myriad, 702 F.Supp.2d at 222.
144. Id. at 223.
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extraction or sequence-reading processes,145 the Myriad decision affirms
many genetic researchers’ beliefs that DNA sequences should be publically
available and is not eligible for patents.146
Importantly, the court’s ruling also affirms the beliefs that DNA
sequences contained within the human genome belong to no specific
individual and should be freely available for all to benefit from.147 Gene
sequences across individual human beings are nearly identical.148 In fact,
all human beings have a version of the cancer-related genes at issue in
Myriad (BRCA1 or BRCA2)149 but only those individuals with slight
differences are at increased risk for developing breast cancer.150 Therefore,
the question as phrased by many is “how can any individual or company
have ownership by means of patent of every person’s gene or sequence at
that location, whether mutant or normal?”151

145. DNA extraction involves breaking apart the cell membrane and then precipitating the
DNA out of the solution. However, these processes do not change or alter the DNA in any way.
See Peter W. Laird et al., Simplified Mammalian DNA Isolation Procedure, 19 NUCLEIC ACIDS
RESEARCH 4293, 4293 (1991). DNA sequencing involves the addition base pairs and then
cleaving the growing strand in order to determine the sequence of the physically purified single
strand DNA. The single strand DNA does not change through the process. See BROWN, supra note
35, at 1–5.
146. See Summary of Principles Agreed at the First International Strategy Meeting on Human
(Feb.
25-28,
1996),
Genome
Sequencing,
GENOMICS.ENERGY.GOV,
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.shtml (last visited Sept.
27, 2010) (stating that officials and scientists from around the world met in Bermuda and agreed
that the human genomic sequence information should be freely available to everyone in order to
maximize the information's benefit to society).
147. See Pilar N. Ossorio, The Human Genome as Common Heritage: Common Sense or Legal
Nonsense?, 35 J.L. MED. & ETHICS 425, 433–34 (2007) (arguing that since the human genome is
part of the common heritage of mankind, it should be considered a form of public property); see
also Melissa Sturges, Comment, Who Should Hold Property Rights to the Human Genome? An
Application of the Common Heritage of Humankind, 13 AM. U. INT’L L. REV. 219, 249 (1997)
(explaining that the human genome is the blueprint of mankind and should be reserved for public
access).
148. Richard Redon, et al., Global Variation in Copy Number in the Human Genome, 444
NATURE 444, 444–54 (2006) (finding only a 12% variance in the genome population from DNA
collected in Europe, America, Africa, and Asia).
149. See BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER INST. (May
29, 2009), http://www.cancer.gov/images/documents/abcb7812-a132-4e78-a532-f002c92fa9b9/
Fs3_62.pdf (“BRCA1 and BRCA2 are human genes that belong to a class of genes known as
tumor suppressors.”).
150. See supra note 140; see also RESNIK, supra note 1, at 159 (“[M]utations of specific genes
known as BRCA1 and BRCA2 are associated with an increased risk of breast and ovarian
cancer.”).
151. See Sturges, supra note 147, at 249–50 (explaining that allowing a private company to
own a patent on the human genome would enable the company to decide what to do with it).
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Additionally, by invalidating the patents in Myriad,152 the court set a
precedent that will help to alleviate the potential and actual harms that gene
patenting has had on scientific and medical discoveries. A recent study by
an advisory panel to the U.S. Secretary of Health and Human Services
found that gene patents are hindering the development of new medical
diagnostic tests while limiting patient access to existing tests.153 Further,
the panel found “the prospect of patent protection of a genetic research
discovery does not play a significant role in motivating scientists to conduct
genetic research.”154 Patents on gene sequences do little to promote
research and discovery while producing significant problems for patients
and researchers.
IV. GENETIC PATENTS AND THE FUTURE OF MEDICINE

Genetic research will continue to provide voluminous data and scientists
will gain more understanding of the importance of specific genetic
sequences.155 Even more important will be the knowledge gained about
epigenetics (the study of gene expression and control caused by
mechanisms other than DNA sequence).156 The genetics research
community is ready to abide by all court rulings and federal policies, but
confusion remains regarding definitions.157

152. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010) (as
amended April 5, 2010).
153. SACGHS Report, supra note 131.
154. Id. at 1.
155. See A Brief Guide to Genomics, NAT’L HUMAN GENOME RESEARCH INST. (Aug. 24,
2010),
http://www.genome.gov/18016863 (recognizing the vast amount of information provided from the
Human Genome and HapMap Projects and stating that a better understanding of genetics will be
important in explaining the role of genes in both health and disease of the human body).
156. See Bob Weinhold, Epigenetics: The Science of Change, 114 ENVTL. HEALTH
PERSPECTIVES 160, 163 (Mar. 2006) (defining epigenetics as “any process that alters gene activity
without changing the DNA sequence, and leads to modifications that can be transmitted to
daughter cells” and stating that epigenetic mechanisms have become one of the most important
considerations for the treatment of cancer).
157. See Christopher E. James, The Impact on Agricultural Research by Genetic Material
Patents and the Need for Clarity and Reform in Patent Law for Genetic Material, 11 DRAKE J.
AGRIC. L. 253, 260 (2006) (stating that a major factor for genetic researchers confusion of their
rights, duties, and liability under the patent laws is due to the “lack of definiteness” of the law);
see also Micheal Risch, Everything is Patentable, 75 TENN. L. REV. 591, 650 (2008) (proposing a
rule to end the subject matter patentability requirement because of uncertainty in the definition
and the inability of the USPTO to distinguish subject matter from the other requirements).
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In determining which patent claims might be eligible for many genetic
methodologies, technologies, and medicines, Bilski leaves scientists and
medical professionals with uncertainty about the patentability of their
inventions and discoveries.158 The continuum of steps required to associate
a specific DNA sequence with a given disease or trait includes a variety of
individual and population studies involving both the direct analysis of the
DNA and the statistical analysis of large data bases.159 However, many of
these processes are now of questionable patent eligibility.160 Especially as
courts re-examine the patent eligibility of gene sequences, the genetics
research community is likely to continue to encourage researchers to share
both methods and results.161 However, when the USPTO or the courts upset
the appropriate balance between intellectual property protection and data
sharing that is necessary for a robust research enterprise,162 the patent
process will continue to confuse and potentially delay the rapid progress
being made in genetic medicine.163
The limits of patentable subject matter will continue to be set through
case law and the organized human genetics community, as well as
individual scientists, will continue to be involved both as legal parties and
158. See e.g., Steve Lohr, Bilski Ruling: The Patent Wars Untouched, N.Y. TIMES BITS BLOG
(Jun. 28, 2010, 7:31 PM), http://bits.blogs nytimes.com/2010/06/28/bilski-ruling-the-patent-warsuntouched/ (explaining that as the Supreme Court refused to provide a ‘bright line’ rule for the
patentability of business methods, the Court’s decision has increased uncertainty benefiting only
the patent litigator).
159. See Mayeux, supra note 52, at 1405 (discussing the procedure, which involves the use of
genetic markers to find specific DNA sequences within the genome and then scientists determine
the likelihood those sequences are associated with a particular disease through calculation of the
odds or lod score).
160. See Steven Seidenberg, Supreme Court Finally Rules in Bilski v. Kappos, INSIDE
COUNSEL,
(Aug.
20,
2010),
http://www.insidecounsel.com/Issues/2010/September
/Pages/Supreme-Court-Finally-Rules-in-Bilski-v-Kappos.aspx (noting many other fields beyond
business methods are at risk of being ruled non patentable as a result of Bilski).
161. See SACGHS Report, supra note 131, at 26–27 (recognizing the norm for academic
scientists to share research results).
162. See Lab. Corp. of Am. Holdings v. Metabolite Labs., 548 U.S. 124, 138 (2006) (Breyer,
J., dissenting) (stating that the Supreme Court should decide a patent case in order to contribute to
the ongoing debate as to whether the patent system reflects the “‘careful balance’ that ‘the federal
patent laws . . . embod[y].’”); see also Harvey S. Perlman, Taking the Protection-Access Tradeoff
Seriously, 53 VAND. L. REV. 1831, 1834 (2000) (recognizing one of the classic rationales for
intellectual property as finding the proper balance between protection and access in order to
maximize the research output).
163. See generally Bryan Nese, Bilski on Biotech: The Potential for Limiting Negative Impact
on Gene Patents, 46 CAL. W. L. REV. 137, 155–56 (2009) (explaining that the profitability of gene
patents can cause researchers to disclose less of their results, and therefore hinder research
progress, to avoid rejection under the novelty aspect of the patent process).
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as amici curiae.164 As the courts struggle to keep up with the pace of
genetic research,165 the best jurisprudence will result from decisions fully
informed by the best scientific and legal principles.

164. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 190–92 (S.D.N.Y. 2010)
(as amended April 5, 2010) (listing eleven different parties as amicus curiae, including
organizations and two individuals: Kenneth Chahine PhD and Kevin E. Noonan PhD).
165. Ryan M.T. Iwasaka, Note, From Chakrabarty to Chimeras: The Growing Need for
Evolutionary Biology in Patent Law, 109 YALE L.J. 1505, 1519 (2000) (urging that the slow and
inconsistent work of the courts and USPTO cannot continue because of the rapid development in
genetic technology).
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